Unresectable Gastroesophageal Junction Adenocarcinoma Recruiting Phase 1 Trials for Sargramostim (DB00020)

IndicationStatusPhase
DBCOND0113409 (Unresectable Gastroesophageal Junction Adenocarcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05269381Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsTreatment